{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T19:05:02Z","timestamp":1779131102606,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"S\u00f6dra Sjukv\u00e5rdsregionen"},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite improved surgical and oncological treatment, ovarian cancer continues to be the most lethal of the gynecologic malignancies. We aimed to analyze survival trends in epithelial ovarian cancer with regard to age, tumor site, and morphology in Sweden 1960 to 2014.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A nationwide population-based study was conducted using data from the Swedish Cancer Registry on 46,350 women aged 18 or older with a diagnosis of epithelial ovarian, fallopian tube, peritoneal, or undesignated abdominal\/pelvic cancer 1960 to 2014. Analyses of age-standardized incidence and relative survival (RS) were performed and time trends modelled according to age, tumor site, and morphology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall incidence of ovarian, tubal, peritoneal, and undesignated abdominal\/pelvic cancers declined since 1980. Median age at diagnosis increased. Serous carcinoma increased in incidence. RS at 1, 2 and 5\u2009years from diagnosis improved since 1960, although not for the youngest and the oldest patients. Ten-year RS did not improve. The best RS was found for fallopian tube cancer and the worst RS for undesignated abdominal\/pelvic cancer. Among the morphologic subgroups, endometrioid carcinoma had the best RS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Survival in epithelial ovarian, tubal, peritoneal, and undesignated abdominal\/pelvic cancers in Sweden has improved over the last six decades. Advances in epithelial ovarian cancer treatment have extended life for the first 5\u2009years from diagnosis but 10-year survival remains poor.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-021-08169-w","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T12:03:17Z","timestamp":1619438597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence and survival of epithelial ovarian, fallopian tube, peritoneal, and undesignated abdominal\/pelvic cancers in Sweden 1960\u20132014: A population-based cohort study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6180-0111","authenticated-orcid":false,"given":"Pia","family":"Leandersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hogberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul W.","family":"Dickman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Malander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christer","family":"Borgfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"issue":"5","key":"8169_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/PAT.0b013e328348a6e7","volume":"43","author":"WG McCluggage","year":"2011","unstructured":"McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420\u201332.","journal-title":"Pathology."},{"issue":"3","key":"8169_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","volume":"460","author":"J Prat","year":"2012","unstructured":"Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237\u201349.","journal-title":"Virchows Arch"},{"issue":"1","key":"8169_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","volume":"124","author":"J Prat","year":"2014","unstructured":"Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2014;124(1):1\u20135.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"8169_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","volume":"107","author":"GD Aletti","year":"2006","unstructured":"Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77\u201385.","journal-title":"Obstet Gynecol"},{"issue":"10","key":"8169_CR5","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353.","journal-title":"N Engl J Med"},{"issue":"3","key":"8169_CR6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0412.2010.01043.x","volume":"90","author":"CL Fag\u00f6-Olsen","year":"2011","unstructured":"Fag\u00f6-Olsen CL, H\u00f8gdall C, Kehlet H, Christensen IJ, Ottesen B. Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstet Gynecol Scand. 2011;90(3):273\u20139.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"8169_CR7","first-page":"149","volume":"42","author":"JP Smith","year":"1975","unstructured":"Smith JP, Rutledge FN, Delclos L. Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. Natl Cancer Inst Monogr. 1975;42:149\u201353.","journal-title":"Natl Cancer Inst Monogr"},{"issue":"2\u20133","key":"8169_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1080\/02841860151116420","volume":"40","author":"T H\u00f6gberg","year":"2001","unstructured":"H\u00f6gberg T, Glimelius B, Nygren P, Care S-gSCoTAiH. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol. 2001;40(2\u20133):340\u201360.","journal-title":"Acta Oncol"},{"issue":"2","key":"8169_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2011.07.098","volume":"123","author":"N Akhtar-Danesh","year":"2011","unstructured":"Akhtar-Danesh N, Elit L, Lytwyn A. Temporal trends in the relative survival among patients diagnosed with ovarian cancer in Canada 1992-2005: a population-based study. Gynecol Oncol. 2011;123(2):192\u20135.","journal-title":"Gynecol Oncol"},{"issue":"9760","key":"8169_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(10)62231-3","volume":"377","author":"MP Coleman","year":"2011","unstructured":"Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011;377(9760):127\u201338.","journal-title":"Lancet."},{"issue":"3","key":"8169_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","volume":"120","author":"LA Baldwin","year":"2012","unstructured":"Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120(3):612\u20138.","journal-title":"Obstet Gynecol"},{"issue":"6","key":"8169_CR12","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1097\/AOG.0000000000000854","volume":"125","author":"JD Wright","year":"2015","unstructured":"Wright JD, Chen L, Tergas AI, Patankar S, Burke WM, Hou JY, et al. Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol. 2015;125(6):1345\u201352.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"8169_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ygyno.2016.10.039","volume":"144","author":"P Dahm-Kahler","year":"2017","unstructured":"Dahm-Kahler P, Borgfeldt C, Holmberg E, Staf C, Falconer H, Bjurberg M, et al. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). Gynecol Oncol. 2017;144(1):167\u201373.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8169_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s12885-018-4498-z","volume":"18","author":"JY Lee","year":"2018","unstructured":"Lee JY, Kim S, Kim YT, Lim MC, Lee B, Jung KW, et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18(1):601.","journal-title":"BMC Cancer"},{"key":"8169_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2017.10.030","volume":"88","author":"M Timmermans","year":"2018","unstructured":"Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RFPM. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2018;88:31\u20137.","journal-title":"Eur J Cancer"},{"key":"8169_CR16","doi-asserted-by":"crossref","unstructured":"Peres LC, Cushing-Haugen KL, K\u00f6bel M, Harris HR, Berchuck A, Rossing MA, et al. Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. J Natl Cancer Inst 2019;111(1):60\u201368.","DOI":"10.1093\/jnci\/djy071"},{"issue":"1","key":"8169_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol (Stockholm, Sweden). 2009;48(1):27\u201333.","journal-title":"Acta Oncol (Stockholm, Sweden)"},{"key":"8169_CR18","unstructured":"World standard population 2011 [Internet]. Available from: https:\/\/seer.cancer.gov\/stdpopulations\/."},{"issue":"2","key":"8169_CR19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/1536867X0900900206","volume":"9","author":"PC Lambert","year":"2009","unstructured":"Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9(2):265\u201390.","journal-title":"Stata J"},{"key":"8169_CR20","first-page":"101","volume":"6","author":"F EDERER","year":"1961","unstructured":"EDERER F, AXTELL LM, CUTLER SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101\u201321.","journal-title":"Natl Cancer Inst Monogr"},{"issue":"15","key":"8169_CR21","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.ejca.2004.07.002","volume":"40","author":"I Corazziari","year":"2004","unstructured":"Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer. 2004;40(15):2307\u201316.","journal-title":"Eur J Cancer"},{"key":"8169_CR22","unstructured":"Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available at https:\/\/www.mortality.org. Accessed 30 Jan 2017."},{"key":"8169_CR23","unstructured":"Statistics Sweden. Available online at: https:\/\/www.scb.se\/en\/. Accessed 20 Aug2018."},{"key":"8169_CR24","doi-asserted-by":"crossref","unstructured":"Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant. 2019.","DOI":"10.1038\/s41409-019-0679-x"},{"issue":"11","key":"8169_CR25","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/ijc.30676","volume":"140","author":"SB Coburn","year":"2017","unstructured":"Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451\u201360.","journal-title":"Int J Cancer"},{"issue":"9609","key":"8169_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","volume":"371","author":"V Beral","year":"2008","unstructured":"Beral V, Doll R, Hermon C, Peto R, Reeves G. Cancer CGoESoO. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303\u201314.","journal-title":"Lancet."},{"issue":"1","key":"8169_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","volume":"149","author":"M Jareid","year":"2018","unstructured":"Jareid M, Thalabard JC, Aarflot M, B\u00f8velstad HM, Lund E, Braaten T. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study. Gynecol Oncol. 2018;149(1):127\u201332.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8169_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9\u201332.","journal-title":"Cancer Biol Med"},{"issue":"3","key":"8169_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321\u201333.","journal-title":"JAMA."},{"issue":"8","key":"8169_CR30","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/ijc.23724","volume":"123","author":"I Sk\u00edrnisd\u00f3ttir","year":"2008","unstructured":"Sk\u00edrnisd\u00f3ttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008;123(8):1897\u2013901.","journal-title":"Int J Cancer"},{"issue":"4","key":"8169_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/aogs.12846","volume":"95","author":"G Kalapotharakos","year":"2016","unstructured":"Kalapotharakos G, H\u00f6gberg T, Bergfeldt K, Borgfeldt C. Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960-2007. Acta Obstet Gynecol Scand. 2016;95(4):473\u20139.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"7","key":"8169_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","volume":"42","author":"RJ Kurman","year":"2011","unstructured":"Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014Shifting the paradigm. Hum Pathol. 2011;42(7):918\u201331.","journal-title":"Hum Pathol"},{"issue":"3","key":"8169_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/PAS.0000000000000550","volume":"40","author":"D Lim","year":"2016","unstructured":"Lim D, Murali R, Murray MP, Veras E, Park KJ, Soslow RA. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. Am J Surg Pathol. 2016;40(3):302\u201312.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"8169_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/00000478-199906000-00001","volume":"23","author":"MA Riopel","year":"1999","unstructured":"Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23(6):617\u201335.","journal-title":"Am J Surg Pathol"},{"key":"8169_CR35","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. Fourth Edition. IARC WHO Classification of Tumours, No 6. Fourth ed: World Health Organization; 2014. p. 307."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08169-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T19:09:50Z","timestamp":1698952190000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08169-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8169"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08169-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"18 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Ethical Review Board, Lund University, Lund, Sweden (DNR 2015\/789). No patient consent was required for participation in this study since the analyses of data from the SCR was performed on a group level, with no access to data that could identify individuals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"465"}}